LDL receptor related protein 5 like (pseudogene)Genealiases: []
Q-omics provides the consensus-scored LRP5L profile across patient tissues and cancer cell-line models. LRP5L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LRP5L is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LRP5L protein abundance shows 24,518 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, COAD, and LSCC as cancer lineages where LRP5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRP5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRP5L survival associations across molecular data types. LRP5L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRP5L RNA expression–survival associations across cancer types. High LRP5L expression shows unfavorable associations in ACC, KICH and COAD, but favorable associations in BLCA, SCLC and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LRP5L RNA expression.
This table summarizes LRP5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRP5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRP5L shows higher tumor expression in COAD, LIHC, HNSC, THCA, UCEC and READ. The COAD box plot shows higher LRP5L RNA expression in tumor versus normal tissue (log2 FC = +0.945, t-test p < 0.001).
This table shows molecular features associated with LRP5L in patient tissues and cancer cell lines. In patient samples, LRP5L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRP5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
